Clinical trial
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
NCT00095238 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00095238 |
|---|---|
| Title | Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) |
| Official title | Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Congestive Heart Failure |
| Intervention type | Drug |
| Interventions | Irbesartan, Placebo |
| Enrollment | 4,128 |
| Start date | Jun 1, 2002 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Nov 2, 2004 |
| Last update posted | Apr 7, 2015 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: